“New Therapeutic Targets in Rare Cancers (NETs and MPNSTs)"
Monday, March 4
Sudro Hall 26
Dawn Quelle, Ph.D.
Associate Professor of Pharmacology, Leader, Cancer Genes and Pathways Program, Holden Comprehensive Cancer Center, Department of Pharmacology at the University of Iowa Carver College of Medicine
The Center for “Diagnostic and Therapeutic Strategies in Pancreatic Cancer”
The Center for “Diagnostic and Therapeutic Strategies in Pancreatic Cancer” (CDTSPC) at NDSU was established with support from the National Institute of General Medical Sciences, under the Center of Biomedical Research Excellence (COBRE) program.
The CDTSPC is focused on the cutting-edge of fundamental research to develop early detection and therapeutic protocols for controlling one of the deadliest forms of cancers—pancreatic cancer. According to the American Cancer Society, the five-year survival rate of pancreatic cancer is about 7 percent. A lack of early symptoms, short survival and resistance to therapy are hallmarks of pancreatic cancer. This highlights the urgent need for new and more effective diagnostic and therapeutic strategies to control the disease.
The CDTSPC supports research of junior investigators interested in pursuing their research career in pancreatic cancer. The Center provides active mentorship, encouraging collaborative research with elite scientists in their disciplines, and facilitating their research programs by developing Core facilities. Two Core facilities—Animal Core and Biostatistics Core—have been established by the CDTSPC. These Cores will further augment the existing biomedical research on campus and help biomedical researchers achieve their research objectives.
The project is supported by the National Institute of General Medical Sciences of the National Institutes of Health, under Award Number 1P20GM109024. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.